Request Demo

Last update 16 May 2025

Cabergoline

Last update 16 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide, (8β)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide, 1-((6-allylergolin-8β-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea

+ [14]

Target

D2 receptor

Action

agonists

Mechanism

D2 receptor agonists(Dopamine D2 receptor agonists)

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic DiseaseSkin and Musculoskeletal Diseases+ [1]

Active Indication

Lactation DisordersParkinson DiseaseHyperprolactinemia

Inactive Indication

Restless Legs Syndrome

Originator Organization

Pfizer Inc.

Active Organization

Strides Pharma Global Pte Ltd.

Pfizer Japan, Inc.

Pfizer Inc.

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

Australia (21 Apr 1995),

Hyperprolactinemia

Regulation-

Structure/Sequence

Molecular FormulaC26H37N5O2

InChIKeyKORNTPPJEAJQIU-KJXAQDMKSA-N

CAS Registry81409-90-7

Clinical Trials associated with Cabergoline

NCT06909123

/ Not yet recruitingPhase 2IIT

A Reduced Dose of Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Pregnancy Loss

Most patients seeking abortion care or management of pregnancy loss in the second trimester will lactate, which can be physically and emotionally painful. The efficacy of a one-time dose of cabergoline has been previously demonstrated to prevent breast symptoms for these patients. This study seeks to determine if investigators can more precisely manage these patients with a reduced dose appropriate for the physiology of the second trimester, thereby reducing the medication cost and reducing or eliminating the uncomfortable medication side effects.

Start Date01 Jul 2025

Sponsor / Collaborator

Stanford University

ChiCTR2400088093

/ SuspendedNot ApplicableIIT

A Non-Interventional Real-World Study on the Use of Cabergoline in the Treatment of Locally Advanced or Metastatic Prostate Cancer

Start Date20 Aug 2024

Sponsor / Collaborator-

CTRI/2024/08/071776

/ Not yet recruitingNot Applicable

To study the efficacy of Cabergoline as an adjunct to Metformin in management of overweight & obese women with PCOS

Start Date17 Aug 2024

Sponsor / Collaborator-

100 Clinical Results associated with Cabergoline

100 Translational Medicine associated with Cabergoline

100 Patents (Medical) associated with Cabergoline

2,380

Literatures (Medical) associated with Cabergoline

01 Jul 2025·CELLULAR SIGNALLING

Mechanisms of constitutive and agonist-induced 5-HT2B internalization, persistent endosomal signaling and paradoxical regulation of agonist pharmacology

Article

Author: Frazer, John ; Chen, Xiaohua ; Dang, Huong ; Unett, David J ; Gaidarov, Ibragim ; Cordova, Isabel ; Sage, Carleton ; Liaw, Chen

Certain ergot derivatives, particularly cabergoline, produce wash-resistant signaling through the 5-HT_2B receptor persisting for many hours without loss of potency or efficacy. Previously, we reported that this signaling may be mediated by sequestered or internalized receptors. Here, we evaluated numerous mechanistic aspects of 5-HT_2B internalization and wash-resistant signaling and directly addressed the role of internalization. In the absence of an agonist, 5-HT_2B undergoes robust, constitutive internalization and recycling and is distributed at equilibrium between cell surface and intracellular compartments. Both constitutive and agonist-induced internalization are mediated through dynamin-dependent clathrin-mediated endocytosis. Constitutive internalization is unaffected by application of 5-HT_2B inverse agonists. We identified two, adjacent di-leucine motifs followed by a di-acidic cluster in the C-terminal tail of 5-HT_2B that are responsible for constitutive internalization of the receptor. Mutations in either of the leucine clusters or in the di-acidic motif partially inhibit constitutive 5-HT_2B internalization. A 5-HT_2B mutant in which both di-leucine clusters are disrupted, displays no constitutive internalization while undergoing robust agonist induced internalization. We demonstrate that wash-resistant signaling of ergots is mediated by persistently/irreversibly internalized signaling receptor complexes. Paradoxically, the potencies of ergot agonists are influenced by receptor internalization; measured potencies are reduced upon inhibition of receptor internalization, while potencies for 5-HT or other conventional agonists are unaffected. This phenomenon represents a novel mechanism by which agonist-dependent kinetics of receptor internalization and recycling affects not only the duration of receptor signaling, but also a basic pharmacological parameter such as agonist potency.

01 Jul 2025·ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Insights into dopaminergic agent cabergoline-induced DNA-destabilisation through spectroscopic, thermodynamic and molecular docking/metadynamics simulation studies

Article

Author: Pavithra, Kandasamy ; Manickam, Vyshnavi ; Elango, Kuppanagounder P ; Priyadharshini, R Durga ; Vennila, K N ; Ragunathan, Preethi

Investigating the interaction of therapeutic drugs with DNA is crucial for assessing the possibility of drugs inducing significant DNA alterations when administered. The dopaminergic drug cabergoline's (CBG) interaction with CT-DNA was investigated using multi-spectroscopic, calorimetric, electrophoresis, and computational approaches. The UV-Vis and fluorescence spectral results certified the complexation of CBG with CT-DNA. Though competitive dye displacement assay, viscosity measurements, ¹H NMR, KI, and urea studies strongly evidenced the intercalation-type binding mode of CBG, the molecular docking studies disclosed CBG as a groove binder as well as a partial intercalator in the minor and major grooves of DNA, respectively. The significant distortions in the characteristic CD bands of CT-DNA and the results of GEL electrophoresis evidenced the DNA-destabilizing nature of CBG. The profound decrease of 7.3 °C in the T_m of CT-DNA in the presence of CBG reiterated CBG as a DNA destabiliser. The results of metadynamics simulation and binding studies of CBG with single-strand DNA showed that the high affinity of CBG towards ssDNA compared to the dsDNA triggered CBG to destabilise dsDNA. Interestingly, the three different thermodynamic parameters resulted in the calorimetric titration of CBG with CT-DNA, exposing the sequential binding pattern involved in the CBG/CT-DNA complexation and proposing the plausible mechanism of CBG-induced DNA destabilisation.

01 Jun 2025·Obstetric Medicine

Postpartum cardiogenic shock with rapid recovery in a Titin gene variant: The role of genetic predisposition in peripartum cardiomyopathy

Article

Author: Karner, Eva ; Schäffl-Doweik, Lilian ; Stöllberger, Claudia ; Laccone, Franco ; Keller, Hans

Peripartum cardiomyopathy is defined as heart failure secondary to left ventricular (LV) dysfunction with a left ventricular ejection fraction <45% occurring towards the end of pregnancy or in the months following delivery without other identifiable cause. Pathogenesis of peripartum cardiomyopathy and the role of genetic variants are unknown. We present a previously healthy 33-year-old woman in her first pregnancy with acute onset of heart failure postpartum. She developed cardiogenic shock four days after caesarean section and was treated with levosimendan, cabergoline, ramipril and bisoprolol. She used a wearable cardioverter/defibrillator for 3 months. After 8 months, she was free of symptoms with normal left ventricular function and brain-natriuretic-peptide-levels. Genetic analysis was carried out due to a positive family history and disclosed a heterozygous variant c7627dupA in the TTN gene. Genetic analysis in patients with a positive family history should be carried out since that may provide insights in the pathogenesis of heart failure due to systolic dysfunction including peripartum cardiomyopathy.

News (Medical) associated with Cabergoline

15 May 2025

·www.prnewswire.com

Cushing's Disease Market Poised for Significant Growth Across the 7MM During the Study Period (2020-2034) with Rising Awareness and Diagnostic Improvements | DelveInsight

The Cushing's disease pipeline possesses some drugs in mid and late-stage development to be approved in the near future. The emerging landscape holds a diverse range of therapeutic alternatives for treatment, including relacorilant, clofutriben, atumelnant, and others. The expected launch of these therapies shall further create a positive impact on the Cushing's disease market. LAS VEGAS, May 15, 2025 /PRNewswire/ -- DelveInsight's Cushing's Disease Market Insights report includes a comprehensive understanding of current treatment practices, Cushing's disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. Key Takeaways from the Cushing's Disease Market Report According to DelveInsight's analysis, the market size for Cushing's disease was found to be USD 1 billion in the 7MM in 2024. In 2024, among all the current therapies for Cushing's disease, the highest revenue was generated by Mifepristone (KORLYM and generics) in the US. Based on DelveInsight's assessment in 2024, the 7MM had approximately 37K diagnosed prevalent cases of Cushing's disease. These cases are expected to rise due to advancements in diagnostic capabilities and increased awareness about the disease during the forecast period (2025–2034). Leading Cushing's disease companies developing emerging therapies, such as Corcept Therapeutics, Sparrow Pharmaceuticals, Crinetics Pharmaceuticals, H. Lundbeck, Stero Therapeutics, and others, are developing novel Cushing's disease drugs that can be available in the Cushing's disease market in the coming years. The promising Cushing's disease therapies in the pipeline include DUPIXENT (dupilumab), Linerixibat (GSK2330672), NEMLUVIO/MITCHGA (nemolizumab), Volixibat, and others. In March 2025, Corcept Therapeutics announced that the FDA had assigned a PDUFA target action date of December 30, 2025, for relacorilant to treat patients with endogenous hypercortisolism. In February 2025, Crinetics Pharmaceuticals mentioned that the company anticipates beginning enrollment for Atumelnant (CRN04894) in Phase Ib/IIa trials for Cushing's disease in late 2025 or early 2026. In October 2024, Sparrow Pharmaceuticals announced that clofutriben had been granted Orphan Drug Designation (ODD) by the US FDA for the treatment of endogenous Cushing's syndrome. Discover which therapies are expected to grab the major Cushing's disease market share @ Cushing's Disease Market Report Cushing's Disease Overview Cushing's disease is a rare but serious endocrine disorder caused by a pituitary tumor that triggers excessive cortisol production. It presents with a variety of symptoms such as weight gain, fatigue, mood disturbances, high blood pressure, and impaired glucose tolerance. Cushing's syndrome is responsible for 80–85% of hypercortisolism cases, with 75–80% of those linked to ACTH-producing pituitary adenomas. Without treatment, the 5-year survival rate is only about 50%, emphasizing the urgent need for effective therapies. Diagnosing Cushing's disease is especially difficult because it is rare, shares symptoms with other disorders, and presents in various ways. Only 40–60% of patients have a detectable tumor on standard Magnetic Resonance Imaging (MRI), and the diagnosis is often delayed by an average of 7 years. Cushing's Disease Epidemiology Segmentation The Cushing's disease epidemiology section provides insights into the historical and current Cushing's disease patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The Cushing's disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Prevalent Cases of Cushing's Disease Total Diagnosed Prevalent Cases of Cushing's Disease Gender-Specific Diagnosed Prevalent Cases of Cushing's Disease Age-Specific Diagnosed Prevalent Cases of Cushing's Disease Cushing's Disease Treatment Market The primary treatment for Cushing's disease is usually transsphenoidal surgery to remove the pituitary tumor, which often leads to remission. However, some patients may experience a recurrence. When surgery is unsuccessful or not an option, medical therapies are used to control cortisol levels. Various medications are available for managing Cushing's disease, especially in cases where surgery is ineffective or not feasible. One such drug is KORLYM, developed by Corcept Therapeutics, approved for treating hyperglycemia in patients with Cushing's syndrome who also have Type 2 diabetes or glucose intolerance. In 2024, a generic version by Teva Pharmaceuticals entered the market, adding competition, and Corcept itself has released a generic version as well. Other approved options include S IGNIFOR and SIGNIFOR LAR, ISTURISA, and RECORLEV. In addition, off-label drugs like ketoconazole, metyrapone, cabergoline, mitotane, and etomidate are also used in the U.S., with some marketed in Europe by HRA Pharma. SIGNIFOR (pasireotide), developed by Recordati, was the first drug specifically approved for Cushing's disease by the FDA in 2012, and also gained EU approval. Recordati also markets SIGNIFOR LAR, a long-acting injectable version approved by the FDA and Japan's PMDA in 2018. This formulation, administered intramuscularly once every four weeks, shares the same mechanism as SIGNIFOR but offers a different delivery route. Recordati is recognized as a leading player in this therapeutic area. Another key product from the company is ISTURISA (osilodrostat), the first FDA-approved oral drug that inhibits cortisol production by targeting the enzyme 11β-hydroxylase (CYP11B1), which is involved in the final step of cortisol synthesis. Its oral administration makes it more convenient for patients compared to injectable therapies. ISTURISA is also being studied for pediatric use in an ongoing Phase II trial (NCT03708900). RECORLEV, originally developed by Strongbridge Biopharma and later acquired by Xeris Pharmaceuticals, was approved by the FDA in 2021. It is indicated for adults with endogenous Cushing's syndrome who are not surgical candidates or did not achieve a cure through surgery. Unlike ISTURISA, RECORLEV works by inhibiting cortisol production at multiple points in the steroidogenesis pathway, offering a distinct mechanism of action. To know more about Cushing's disease treatment guidelines, visit @ Cushing's Disease Management Cushing's Disease Pipeline Therapies and Key Companies Relacorilant (CORT125134): Corcept Therapeutics Clofutriben (SPI-62): Sparrow Pharmaceuticals Atumelnant (CRN04894): Crinetics Pharmaceuticals Lu AG13909: H. Lundbeck ST-002: Stero Therapeutics Discover more about Cushing's disease drugs in development @ Cushing's Disease Clinical Trials Cushing's Disease Market Dynamics The Cushing's disease market dynamics are expected to change in the coming years. Although Cushing's disease is generally considered a rare condition, growing awareness and recent advances in research suggest that diagnoses may rise in the future; despite a seemingly crowded market, many current hypercortisolism treatments fail to normalize cortisol levels effectively and pose significant side effects highlighting a substantial opportunity for innovation, especially given the limited therapies specifically targeting Cushing's disease and the potential of newer oral alternatives like ISTURISA and RECORLEV to offer greater flexibility compared to SC and intramuscular options such as SIGNIFOR and SIGNIFOR LAR. Furthermore, potential therapies are being investigated for the treatment of Cushing's disease, and it is safe to predict that the treatment space will significantly impact the Cushing's disease market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the Cushing's disease market in the 7MM. However, several factors may impede the growth of the Cushing's disease market. Due to non-specific guidelines and recommendations, patients with Cushing's disease often face suboptimal care, delayed diagnosis, and inconsistent treatment approaches, further compounded by the diagnostic complexity, frequent misdiagnosis, and symptom overlap with more common conditions, which leave many undiagnosed or untreated; while existing therapies such as ketoconazole and metyrapone approved in Europe based on limited retrospective data and used off-label in the US despite high costs are widely trusted and entrenched in clinical practice, posing a significant barrier to the adoption of emerging therapies. Moreover, Cushing's disease treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the Cushing's disease market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the Cushing's disease market growth. Scope of the Cushing's Disease Market Report Therapeutic Assessment: Cushing's Disease current marketed and emerging therapies Cushing's Disease Market Dynamics: Key Market Forecast Assumptions of Emerging Cushing's Disease Drugs and Market Outlook Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Cushing's Disease Market Access and Reimbursement Download the report to understand which factors are driving Cushing's disease market trends @ Cushing's Disease Market Trends Table of Contents Related Reports Cushing's Syndrome Market Cushing's Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Cushing's syndrome companies including Corcept Therapeutics, Crinetics Pharmaceuticals, Cyclacel Pharmaceuticals, Sparrow Pharmaceuticals, Stero Therapeutics, among others. Cushing's Syndrome Pipeline Cushing's Syndrome Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Cushing's syndrome companies, including Corcept Therapeutics, Crinetics Pharmaceuticals, Cyclacel Pharmaceuticals, Sparrow Pharmaceuticals, Stero Therapeutics, among others. Endogenous Cushing's Syndrome Market Endogenous Cushing's Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endogenous Cushing's syndrome companies including Corcept Therapeutics, Crinetics Pharmaceuticals, Sparrow Pharmaceuticals, among others. Endogenous Cushing's Syndrome Pipeline Endogenous Cushing's Syndrome Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endogenous Cushing's syndrome companies, including Corcept Therapeutics, Crinetics Pharmaceuticals, Sparrow Pharmaceuticals, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug ApprovalOrphan DrugPhase 2

02 Dec 2024

·www.drugs.com

Guidelines Developed for Treatment of Restless Legs Syndrome

MONDAY, Dec. 2, 2024 -- In a clinical practice guideline issued by the American Academy of Sleep Medicine and published online Sept. 26 in the Journal of Clinical Sleep Medicine , recommendations are presented for the treatment of restless legs syndrome (RLS). John W. Winkelman, M.D., Ph.D., from Massachusetts General Hospital in Boston, and colleagues developed recommendations for treatment of RLS and periodic limb movement disorder in adults and pediatric patients. The researchers developed three good practice statements that were based on expert consensus. They recommend all clinicians should regularly test serum iron studies, including ferritin and transferrin saturation, in all patients with clinically significant RLS, ideally in the morning; analysis of these studies influences the decision to use oral or intravenous (IV) iron treatment. The authors also state that addressing exacerbating factors, including alcohol, caffeine, antihistaminergic, serotonergic, and anti-dopaminergic medications, should be the first step in RLS management. They note RLS is common in pregnancy and the pregnancy-specific safety profile of each treatment should be considered. Recommendations for adults with RLS include use of gabapentin enacarbil over no gabapentin enacarbil; use of gabapentin over no gabapentin; use of pregabalin over no pregabalin; and use of IV ferric carboxymaltose over no IV ferric carboxymaltose for those with appropriate iron status (strong recommendations; moderate certainty of evidence). In addition, there is a strong recommendation against use of cabergoline. "Guided by the best evidence in the scientific literature, we've provided recommendations that will improve the ability of clinicians to provide patient-centered care for people who have RLS," Winkelman said in a statement. One author disclosed ties to the pharmaceutical and medical device industries. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

06 Dec 2021

·www.pharmaindustrial-india.com

IPC adds 9 new IP impurities standards

The Indian Pharmacopoeia Commission (IPC) has added 9 new IP impurities standards which includes Bromhexine Hydrochloride Impurity C, Cabergoline Impurity A, Cilostazol Impurity B, Citalopram Impurity B, Fosinopril Impurity A, o-toluene sulfonamide, p-toluene sulfonamide, Tributyl o-acetyl citrate/Acetyl Tributyl citrate, Vildagliptin Impurity D. Impurity standards are used to perform the system suitability, qualitative and quantitative parameters for compliance to Indian Pharmacopoeia monograph. The commission stated that certain monographs require the use of a chemical reference substance or a biological reference preparation or a reference spectrum. IPC in collaboration with USP also conducted a webinar on “Fundamentals of Dissolution” as a part of Capability Building initiative. The webinar was conducted “exclusively” for MSME (Micro, small and medium enterprises). The session conducted by Dr. Rajeev Singh Raghuvanshi - Secretary-cum-Scientific Director, IPC and Josan Thomas, Scientific Liaison, USP India, covered the science behind dissolution, fundamentals of dissolution testing, and specifics related to the qualification of USP apparatus 1 and apparatus 2. The session saw great response with 339 participants from 149 unique companies. The panelists for webinar includes Dr. Rajeev Singh Raghuvanshi - Secretary-cum-Scientific Director, IPC, Dr. Robin Kumar - Principal Scientific Officer, Dr. Gaurav Pratap Singh Jadaun - Senior Scientific Officer, IPC, Josan Thomas, Scientific Liaison, USP India, Mr. Girish Kapur- Vice President, USP India, Joseph Eaton - Senior Manager, USP Rockville. The vision of IPC is to promote the highest standards of drugs for use in human and animals within practical limits of the technologies available for manufacture and analysis. IPC is an autonomous institution of the ministry of health and family welfare, Government of India. IPC is created to set standards of drugs in the country. Its basic function is to update regularly the standards of drugs commonly required for treatment of diseases prevailing in this region. The mandate of the commission is to perform, inter-alia, functions such as revision and publication of the Indian Pharmacopoeia and National Formulary of India on a regular basis besides providing IP reference substances and training to the stakeholders on pharmacopoeial issues

100 Deals associated with Cabergoline

External Link

KEGG	Wiki	ATC	Drug Bank
D00987	Cabergoline	N04BC06 G02CB03	DB00248

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Lactation Disorders	Japan	Pfizer Japan, Inc.	16 Apr 2003
Parkinson Disease	Japan	Pfizer Japan, Inc.	16 Jun 1999
Hyperprolactinemia	Australia	Pfizer Inc.	21 Apr 1995

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Restless Legs Syndrome	Phase 3	-	Pfizer Inc.	01 Nov 2002

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01794793 (B2412, CTgov)	Phase 4	Pituitary ACTH Hypersecretion \| Dumping Syndrome \| Pituitary Neoplasms ... View more	337	Cabergoline+Pasireotide (Pasireotide Subcutaneous)	lmjsylhxxo = kctdzzsflo jwiylsbhbe (junuvvhyzl, trmhalzsbx - hmuywshvxf) View more	-	28 Aug 2024
				Pasireotide LAR (Pasireotide Long Acting Release (LAR))	lmjsylhxxo = evveredwsu jwiylsbhbe (junuvvhyzl, asruymfipf - awouutjhui) View more
ENDO2024	Not Applicable	-	-	Cabergoline 0.5 mg	ocvbyfkiaa(kkusxizijw) = pcxpfjofps tvospsmhwb (mmbkcfnsut, 7.2 - 63.3) View more	-	01 Jun 2024
NCT05024422 (Pubmed \| Am J Obstet Gynecol)	Phase 3	Breast Feeding	-	Cabergoline	hdgwaepwtu(gychjataar) = dodscfkqaz xvdpruqayf (ksjejfkhdn ) View more	Positive	01 May 2024
				Pyridoxine	hdgwaepwtu(gychjataar) = ghelexluds xvdpruqayf (ksjejfkhdn ) View more
THU028 (ENDO2023)	Not Applicable	Acromegaly	2	Oral Octreotide	wvcrtnupqy(dwbatencqm) = aryvqtxnnk xeojilmaiu (grylukoncn ) View more	Positive	05 Oct 2023
				Cabergoline	wvcrtnupqy(dwbatencqm) = utehoktgan xeojilmaiu (grylukoncn ) View more
NCT04701333 (Pubmed \| Obstet Gynecol)	Phase 2	Abortion	73	Cabergoline 1 mg	idaybiyoxn(rlrrhcvzpc) = ntmsijqshu eatzhpdeeb (owenlsaukl )	Positive	01 Jun 2023
				Placebo	idaybiyoxn(rlrrhcvzpc) = hvwbgvqabp eatzhpdeeb (owenlsaukl )
NCT04701333 (LISTA, CTgov)	Phase 2	Breast Feeding \| second trimester abortion	73	Cabergoline 1 MG (Cabergoline)	ltawpvljup = tlwmctepkj irojqirxpe (raohccawka, cbkxyroshs - vvbnguqjsm) View more	-	05 Apr 2023
				Placebo (Placebo)	ltawpvljup = fqhhdyppox irojqirxpe (raohccawka, yusxqirjll - obsodsowya) View more
ODP299 (ENDO2022)	Not Applicable	Prolactinoma	1	Cabergoline 1.5mg/week	pxzrqivxqk(vykdhsbcdv) = khhcjsvksw ziavzgxhta (murgukaepw ) View more	Positive	01 Nov 2022
				Cabergoline 4mg/week	pxzrqivxqk(vykdhsbcdv) = esvdscxwra ziavzgxhta (murgukaepw )
ENDO2021	Not Applicable	Pituitary Adenoma	-	Cabergoline	bvzsqikhbe(kynrozbkld) = rktupwvizx atupzvoyln (pezetwmqjl ) View more	Positive	03 May 2021
ASTRO2020	Not Applicable	Glioblastoma	-	Dose-Intensified Chemoradiation (Standard chemoradiation)	hmhbcdhhut(zwlodzgjeh) = 2 cases observed nyiguvniwe (aamjpbtdpa ) View more	-	01 Nov 2020
MDS2020	Not Applicable	Parkinson Disease	3	Low dose Cabergoline	zeltzzyqud(casrosfgch) = evzdgolonl mnqvnosolu (qeipzdflxs )	-	12 Sep 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis